Exclusive: White House kept FDA in the dark on Russian ventilators for
New York and New Jersey
Send a link to a friend
[May 30, 2020]
By Marisa Taylor
(Reuters) - When U.S. President Donald
Trump agreed to accept a shipment of ventilators from Russian President
Vladimir Putin at the height of the coronavirus outbreak, the White
House did not alert the FDA as it headed to New York and New Jersey,
Reuters has learned.
Instead, the Food and Drug Administration heard about the arrival of the
shipment from the Federal Emergency Management Agency (FEMA) on March
31st, the day before the 45 Aventa-M ventilators were delivered, the
health regulator told Reuters.
At the time, the states were girding for a crush of COVID-19 patients
likely to need intensive care and thousands of ventilators to help them
breathe.
New Jersey and New York did not end up using the ventilators. But
details first reported by Reuters about the shipment has drawn scrutiny
from Congressional Democrats. The last minute notification meant the
ventilators headed for the epicenter of the U.S. coronavirus outbreak
did not first receive FDA authorization.
"FEMA and FDA were aware in general of items included on the flight, but
did not have all details on the products before the shipment arrived on
April 1,” an FDA spokeswoman said.
Earlier this month, Russia suspended use of some of the Aventa-M
ventilators in its own hospitals after six people died in fires that
reportedly involved the devices.
New York Congresswoman Carolyn Maloney, who oversees the House Oversight
and Reform Committee, said the Reuters report raises “serious concerns
about whether President Trump and his aides at the White House may have
kept FDA experts in the dark while they rushed to bring in these
ventilators from Russia.”
The White House declined to comment on its role, and previously referred
to a FEMA statement that had emphasized the urgent need for the
ventilators.
“Russia sent us a very, very large planeload of things, medical
equipment, which was very nice," Trump said on March 30.
A day later, the Russian embassy announced that “Russia may send a plane
with medical equipment and protection gear to the United States.”
[to top of second column]
|
A shipment containing medical aid from the United States, including
50 ventilators, is carried after being unloaded from a U.S. Air
Force C-17 Globemaster transport plane at Vnukovo International
Airport amid the coronavirus disease (COVID-19) outbreak in Moscow,
Russia May 21, 2020. REUTERS/Evgenia Novozhenina/Pool/File Photo
U.S. officials have said the ventilators were never supplied to
local hospitals, which ultimately did not need as many as feared,
and they are being returned to FEMA.
As it turned out, the Aventa-M ventilators required an electrical
voltage not compatible in the United States, a New Jersey health
official told Reuters.
To help cope with the fast-spreading coronavirus pandemic that has
now infected more than 1.7 million Americans and killed over
100,000, the FDA had introduced an emergency protocol to allow
ventilators to be distributed without the agency's routine, and more
time-consuming, approval process.
The Russian ventilators, however, did not even receive the FDA's
expedited Emergency Use Authorization (EUA) before being delivered
to New York and New Jersey, the agency told Reuters. The FDA has
issued EUAs for ventilators from other sources.
Maloney joined other Democrats in expressing alarm this week about
the way the U.S. government went about accepting the Russian
equipment, and its decision to later ship U.S. ventilators to Russia
while the epidemic is still underway at home.
"It is troubling that potentially unsafe medical devices were able
to enter the U.S. apparently with minimal or no formal regulatory
review,” New Jersey Congressman Frank Pallone, Jr., who chairs the
House Energy and Commerce Committee that has oversight of the FDA,
said in a statement.
(Reporting by Marisa Taylor in Washington; Editing by Bill Berkrot)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|